Amphastar PharmaceuticalsAMPH
Recorded

Amphastar Pharmaceuticals 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration33 minParticipants11

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Please note that certain statements made during this call regarding matters that are not historical facts, including but not limited to management's outlook or predictions for future periods, are forward-looking statements. These statements are based solely on information that is now available to us. We encourage you to review the session entitled Forward-Looking Statements in the press release issued today and the presentation on the company's website. Also, please refer to our SEC filings, which can be found on our website and the SEC's website for a discussion of numerous factors that may impact our future performance. We will also discuss certain non-GAAP measures. Important information on our use of these measures and reconciliations to U.S. GAAP may be found in our earnings release. Please note this conference is being recorded.

Operator

Our speakers today are Mr. Bill Peters, CFO, Mr. Dan Dischner, Senior Vice President of Corporate Communications, and Mr. Tony Marrs, Executive Vice President of Regulatory Affairs and Clinical Operations. I will now turn the conference over to your host, Mr. Dan Dischner, Senior Vice President of Corporate Communications. Dan, you may begin. Thank you, Paul.

Dan DischnerSVP of Corporate Communications

Good afternoon, everyone, and thank you for joining Amphastar's third quarter 2026 earnings call. Earlier today, we reported our financial results for the third quarter ended September 30, 2026, which are available on the Investors page of our website. The third quarter was marked by record commercial performance, continued progress on our IMS remediation efforts, and further advancements of our development pipeline. We achieved quarterly revenue of $207.6 million, up approximately 8% year-over-year and 13% sequentially. Growth was driven primarily by strong performance from BAQSIMI and Primatene MIST, supplemented by contributions from recently launched products. Gross margin decreased during the quarter, primarily driven by the impact of lower net pricing on certain products and higher manufacturing expenses, including costs associated with the remediation efforts at our IMS manufacturing facility.

Dan DischnerSVP of Corporate Communications

Bill will provide additional detail on these factors as well as the year-over-year earnings comparison in the financial review. Our strategy remains focused on three complementary growth priorities. First, maximizing the growth of BAQSIMI and Primatene MIST while expanding our differentiated commercial portfolio. Second, advancing our pipeline of complex generics and biosimilars. And third, progressing our proprietary development program. Our scientific, manufacturing, and commercial capabilities support each of these initiatives. I would like to provide an update on each, beginning with our commercial portfolio. BAQSIMI delivered record quarterly net sales of $58.8 million, representing growth of approximately 10% compared to the prior year's period. The increase was driven by higher unit volumes, partially offset by lower net pricing associated with commercial discounts and customer mix. During the quarter, the measures we implemented to address duplicate 340B discounts continued to produce results, further reducing their impact relative to the second quarter.

Dan DischnerSVP of Corporate Communications

We remain focused on driving prescription growth, expanding patient access, and executing our commercial strategy to maximize the long-term value of the franchise. Primatene MIST delivered record quarterly net sales of $31.5 million, an increase of approximately 9% compared to the prior year's period. Growth was driven by both the price increase implemented in the second quarter and higher unit volumes, with in-store unit sales increasing approximately 2.5% year over year. These results highlighted the strength of our commercial operation and our ability to successfully manage differentiated pharmaceutical products across multiple markets and distribution channels. More recent product launches also contributed meaningfully during the quarter. Specifically, ipratropium bromide, which launched in April, generated $6.6 million in sales, while teriparatide contributed $6.4 million. These launches supported overall portfolio growth and partially offset headwinds affecting certain established products, including glucagon injections.

Dan DischnerSVP of Corporate Communications

Our commercial portfolio continues to provide the cash flow and operational foundation needed to invest in the development, manufacturing, and commercial capabilities that support our pipeline of complex generics, biosimilars, and proprietary medicines. During the quarter, we continued to invest in manufacturing initiatives that support both our existing portfolio and future growth opportunities, and activities related to our insulin and proprietary development program. Our U.S.-based manufacturing footprint and vertically integrated operating model remain important competitive advantages as we prepare for future product launches. We also remain focused on addressing matters related to our IMS facility. Following the FDA's warning letter received earlier this year, we continue to implement corrective actions and advance our remediation efforts. These activities affected production schedules and the timing of certain product releases during the quarter, resulting in lower sales of certain IMS manufacturing products and higher manufacturing expenses.

Dan DischnerSVP of Corporate Communications

It is important to note the impact to date has been primarily operational in nature rather than demand-related. We continue to work closely with the FDA while maintaining the supply of essential medicines, including products that help address ongoing drug shortages. At the same time, we remain committed to fully addressing the agency's observations, maintaining the supply of important medicines, and achieving sustainable improvements in our quality and manufacturing systems. Bill will provide additional detail on the financial impact of these activities, our current expectations for remediation-related spending, and our broader business outlook. Turning to the second and third pillars of our growth strategy, we continue to make progress across our development pipeline during the quarter. For our insulin aspart biosimilar and interchangeable program, we remain on track to support a potential commercial launch in 2027, subject to FDA approval.

Dan DischnerSVP of Corporate Communications

During the quarter, we advanced the clinical and manufacturing activities needed to support the program and continued preparing for commercialization. Development activities also remain ongoing across our broader biosimilar portfolio, as well as additional complex inhalation and injectable product candidates. Our proprietary pipeline also remains an important part of our long-term growth strategy. For AMP-101, our intranasal epinephrine program, we continued clinical development activities following the initiation of our phase I program in the second quarter. In the third quarter, we refined the study design and formulation based on regulatory feedback as we continue to advance the clinical development program. We believe AMP-101 has the potential to provide patients with an additional non-injectable treatment option for severe allergic reactions, including anaphylaxis.

Dan DischnerSVP of Corporate Communications

For AMP-109, our peptide-coupled docetaxel oncology program, we continued non-clinical studies and manufacturing preparations during the quarter, building on the constructive FDA feedback received earlier this year regarding our proposed development approach. We also continued development of AMP-110, our synthetic human corticotropin program, including the evaluation of potential therapeutic indications and additional non-clinical studies to support a clinical development program. Development activities also continued for AMP-107, our proprietary ophthalmic program targeting wet age-related macular degeneration and diabetic macular edema. Our goal is to develop a differentiated eye drop treatment alternative for conditions currently treated primarily through intraocular injection, which we believe significant unmet needs remain. While these programs remain in early stages of development, we believe they represent meaningful long-term opportunities, and we are focused on disciplined investment as we advance them toward key development milestones.

Dan DischnerSVP of Corporate Communications

I will now turn the call over to Bill Peters, our CFO and Executive Vice President of Finance, for a more detailed third quarter financial review.

Bill PetersCFO

Bill? Thank you, Dan. Good afternoon, everyone.

Bill PetersCFO

In my comments today, I will discuss the third quarter results and then update some of our assumptions for 2026. Revenues for the third quarter increased 8% to $207.6 million, which is the highest amount we have ever recorded in one quarter. This compares to $191.8 million of revenue in the previous year's period. Epoprostenol bromide inhalation, which we launched in April, led the growth with strong sales of $6.6 million. BAQSIMI revenues increased 10% to $58.8 million compared to $53.6 million in the prior year period, primarily due to an increase in units sold, contributing $7.4 million in sales, driven by our continued marketing efforts.

Bill PetersCFO

This increase was partially offset by lower average selling prices, which negatively impacted sales by approximately $2.2 million, primarily as a result of higher rebates and higher 340B pharmacy discounts, some of which may have been duplicated. Although rebates and 340B discounts remained a year-over-year pricing headwind, the impact was significantly smaller than in the previous two quarters, reflecting the positive impact of the measures we implemented to identify and resolve potential duplicate 340B discounts. Primatene MIST sales rose 9% to $31.5 million in the third quarter, up from $28.8 million in the third quarter of last year, due to both a recent price increase and an increase in unit volume, as we continue to see strong in-store demand.

Bill PetersCFO

Sales of lidocaine increased 29% to $16.6 million from $12.9 million in the prior year period, driven by higher demand due to a shortage from another supplier. Epinephrine sales decreased 19%, $15.3 million from $18.8 million in the prior year period, primarily due to slower product releases at our IMS facility as a result of the remediation efforts related to the FDA warning letter. Glucagon sales declined 37% to $8.6 million from $13.6 million due to increased competition. Other pharmaceutical product sales increased 9% to $70.2 million from $64.1 million, primarily due to sales of teriparatide, contributing $6.4 million, which we launched in December 2025. API sales of $6.2 million from our ANP subsidiary also had a positive impact on sales.

Bill PetersCFO

These increases were partially offset by a decrease in sales for several IMS products as a result of the remediation efforts at that facility. Cost of revenues increased 16% to $108 million from $93.2 million, and gross margins decreased to 48% of revenues in the third quarter of 2026 compared to 51% in the previous year's period. The primary drivers of the change were lower average selling prices for BAQSIMI, glucagon, and our epinephrine multi-dose vial product. Additionally, we had increased manufacturing costs at our IMS facility related to the remediation efforts. These factors were partially offset by sales of recently launched products with higher margins, such as ipratropium bromide and teriparatide. Selling, distribution, and marketing expenses increased 4% to $11.9 million from $11.5 million, primarily due to higher freight expense.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day